Navigation Links
Labopharm announces details for first quarter results conference call and annual meeting
Date:5/1/2008

LAVAL, QC, May 1 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced the dates and times of its first quarter fiscal 2008 results conference call and Annual Meeting of Shareholders.

First Quarter Results Conference Call

On Thursday, May 8 at 8:30 a.m. (ET) Labopharm will host a conference call to discuss its first quarter 2008 financial results. Labopharm will report its first quarter 2008 financial results via news release at approximately 7:00 a.m. the same day.

To access the conference call by telephone, dial 416-644-3428 or 1-800-731-5774. Please connect approximately 15 minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until Thursday, May 15, 2008 at midnight. To access the archived conference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservation number 21270272 followed by the number sign.

A live audio webcast of the conference call will be available at http://www.labopharm.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above web site for 30 days.

Annual Meeting of Shareholders

Labopharm will hold its Annual Meeting of Shareholders on Thursday, May 8 at 11:00 am ET at the Montreal Museum of Fine Arts, Maxwell-Cummings Auditorium, 1379 Sherbrooke Street West, Montreal, Quebec.

A live webcast of the meeting will be available at http://www.labopharm.com. Please connect at least 15 minutes prior to the meeting to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above website for 30 days.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit http://www.labopharm.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the uncertainties related to the outcomes of clinical trials, the regulatory process in various countries for the approval of the Company's products and the successful commercialization of the products throughout the world if they are approved. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Labopharm Appoints Dr. Claire Brulle as Senior Vice-President and Chief Medical Officer
2. Labopharm Appeals FDAs Decision on Once-Daily Tramadol to Next Supervisory Level After Additional Analysis Supports Efficacy
3. Labopharm Initiates Phase III Clinical Trial for Twice-Daily Formulation of Tramadol-Acetaminophen
4. Labopharms Once-Daily Tramadol Approved in South Korea and Australia
5. Labopharm to host conference call Thursday, February 21, 2008 at 8:30 a.m. (ET)
6. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
7. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
8. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
9. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
10. Labopharm Reports Results for Third Quarter Fiscal 2007
11. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... ... Old School Labs™, makers of the wildly popular all-natural sports supplements based ... its growing team of brand ambassadors. The Olympia top finisher and former Big 12 ... year was able to turn professional, participating in the 2013 NPC USA Championships in ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... programs and resources at seafoodnutrition.org/programs and seafoodnutrition.org/resources to assist in teaching communities ... These resources have been developed for use by nutrition educators and influencers ...
(Date:1/22/2017)... (PRWEB) , ... January 22, 2017 , ... Zifam Pinnacle, ... across the world, recently met with big-name retail buyers at the January ECRM Trade ... of efficacy and uses the utmost safety standards in all of its creations to ...
(Date:1/21/2017)... Viejo, California (PRWEB) , ... January 21, 2017 , ... "ProDOF is the perfect set ... one subject to another subject in a scene," said Christina Austin - CEO of Pixel ... a given scene. Easily create the illusion of a DSLR racking focus from one ...
(Date:1/21/2017)... Rosa, CA (PRWEB) , ... January 21, 2017 ... ... the opening of its new medical office in Petaluma, located at 167 Lynch ... casting room, access to SRO sports medicine and rehabilitation services and ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... -- Ahead of today,s trading session, Stock-Callers.com draws investors, ... at the close: Kite Pharma Inc. (NASDAQ: KITE ), ... and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ). According to ... Friday, January 20 th , 2017, down on the day by ... stocks now at: ...
(Date:1/23/2017)... , 23 janvier 2017  ResMed (NYSE : RMD), ... , Floride) ont annoncé aujourd,hui qu,ils se sont mis ... existants entre les parties. BMC et 3B seront autorisés ... de droits à ResMed, et ResMed effectuera le paiement ... pour clore le litige de Floride entre les deux ...
(Date:1/23/2017)... weeks remain until legal experts and senior industry leaders involved in supply ... to discuss the flow of pharmaceutical products post Brexit at the ... . In the run up to the show, SMi Group ... in the event download centre . ... Some of those confirmed include: EMA, Aeterna ...
Breaking Medicine Technology: